Driven by Q-linea's strong commercial progression with a growing customer base, Q-linea today announced a cost efficiency program to optimise the organisation and cost structure to meet the increasing needs from customers. The company is re-allocating resources from development to market-facing roles, with an emphasis on the US, while simultaneously reducing operational costs by 10 percent from reported levels in the Q3 2025 report. Full savings are anticipated from the second quarter 2026.
Following the company's success in completing major development projects during 2025, savings potential has been identified across facilities, development, project execution and corporate functions. During early 2026 the company will consolidate the Swedish offices to its manufacturing facility in Uppsala. Development will continue in Uppsala on priority programs to expand the ASTar testing menu for non-blood isolates and Gram-positive infections, which are expected to drive sales by capitalising on the installed base of ASTar instruments.
A negotiation process for the new organization has been initiated together with the unions. In total, the cost reduction is expected to be approximately SEK 16 million per annum with anticipated restructuring costs of SEK 3 million.
The company previously announced efficiency gains realised by insourcing the production of consumables, which will significantly reduce cost of goods sold and enable operational scalability. Combined with a lower personnel and non-personnel operating costs and a customer-centric organisational structure, Q-linea increases its focus on the drive to profitability and a breakeven during 2027.
For more information, please contact:
Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20
About Q-linea
Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner - when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com
This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-10-22 13:30 CEST.
